Diagnosis and Management of Acute Myeloid Leukemia (AML)
Diagnostic Confirmation
- The American Society of Hematology recommends that a bone marrow aspiration with a differential count of 500 cells be performed as a standard diagnostic procedure, although if the peripheral blast count is ≥30%, diagnostic studies can be performed on peripheral blood 1, 3
- The National Comprehensive Cancer Network (NCCN) suggests that a diagnosis of AML requires ≥20% blasts in bone marrow or peripheral blood, counting myeloblasts, monoblasts, and megakaryoblasts 1, 3, 5
Morphological and Cytochemical Studies
- The European LeukemiaNet recommends that Romanowsky staining (May-Grünwald-Giemsa or Wright-Giemsa) be performed on bone marrow and peripheral blood smears 1, 4
- The presence of myeloperoxidase (MPO) or Sudan Black B positivity in ≥3% of blasts confirms myeloid lineage 1, 3
Immunophenotyping by Multiparameter Flow Cytometry
- The NCCN recommends that immunophenotyping be performed to determine cellular lineage and should be done with at least 3-4 colors 1, 5
- Myeloid markers include CD13, CD15, CD16, CD33, CD65, and cytoplasmic myeloperoxidase (cMPO) 1
Cytogenetic and Molecular Analysis
- The European LeukemiaNet recommends that conventional cytogenetic analysis be a mandatory component in the diagnostic evaluation of all patients with suspected AML 1, 5
- Cytogenetic abnormalities are detected in approximately 55% of AML cases and are the most important prognostic factor 1
- Favorable cytogenetics include t(8;21), inv(16), t(16;16), and t(15;17) 1, 6
Initial Critical Evaluation
- The NCCN recommends that urgent laboratory studies include complete blood count with differential, complete chemistry panel, LDH, and uric acid 5
- Coagulopathy is common in AML presentation and should be evaluated before invasive procedures 5
Risk Stratification and Management
- The European LeukemiaNet recommends that patients be stratified into favorable, intermediate, and adverse risk groups based on cytogenetics and molecular abnormalities 6
- Favorable risk includes t(8;21), inv(16), t(16;16), and t(15;17), with a better prognosis 1, 6
- Adverse risk includes complex karyotype, anomalies of chromosomes 5 and 7, 11q23 (except t(9;11)), inv(3), and t(6;9), with an adverse prognosis 1, 6
Treatment of Induction
- The NCCN recommends that induction chemotherapy for patients under 60 years old consist of one or more courses of cytarabine plus an anthracycline or anthracycline derivative 5
- The goal of induction therapy is to achieve complete remission, defined as the absence of morphological evidence of leukemia after recovery of peripheral blood counts 5
Special Considerations
- The European LeukemiaNet recommends that patients with adverse prognostic factors be considered for investigational therapeutic strategies or early allogeneic transplant, as they show little benefit with conventional therapy 3
- If the morphology shows abnormal promyelocytes with intense granulation or microgranular variant, or if there is severe coagulopathy, ATRA should be initiated immediately before genetic confirmation and discontinued only if t(15;17) or PML-RARA fusion is not confirmed 4, 7